A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
2 other identifiers
interventional
N/A
2 countries
9
Brief Summary
This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2002
CompletedFirst Posted
Study publicly available on registry
April 30, 2002
CompletedJuly 19, 2006
July 1, 2006
April 29, 2002
July 18, 2006
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Histologic or cytologic diagnosis of locally or metastatic colorectal cancer
- Prior therapy with 5-FU for metastatic cancer
- Adequate bone marrow, liver and kidney function
You may not qualify if:
- Pregnancy
- Breast feeding
- Inability to interrupt aspirin therapy
- Brain metastasis
- Patients who have been treated previously with ALIMTA or irinotecan
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Wichita, Kansas, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
New York, New York, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Pittsburgh, Pennsylvania, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Bielefeld, North Rhine-Westphalia, Germany
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Halle, Germany
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Hamburg, Germany
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Homburg/Saar, Germany
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Magdeburg, Germany
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
München, Germany